Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
Ginkgo Bioworks Holdings, Inc. (DNA) Form 144 notifies the proposed sale of 10,000 Class A shares through Fidelity Brokerage Services with an aggregate market value of $110,599.54. The filing reports the shares were acquired on 03/11/2022 via restricted stock vesting as compensation. The approximate sale date is listed as 09/09/2025 on the NYSE, and the issuer has 47,089,598 shares outstanding. The filer disclosed a prior sale of 10,000 shares on 09/08/2025 that generated gross proceeds of $109,209.34. The notice includes the standard attestation that no undisclosed material adverse information is known.
Ginkgo Bioworks (DNA) Form 144 notice: An insider notified the sale of 10,000 Class A shares through Fidelity Brokerage Services (900 Salem St, Smithfield RI) with an approximate aggregate market value of $109,209.3447,089,598 and an approximate sale date of 09/08/2025. All 10,000 shares were acquired from the issuer as restricted stock vesting on dates between 11/19/2021 and 03/11/2022 and were paid as compensation. The filer reports no securities sold in the past three months.
Ginkgo Bioworks Holdings entered into a Sales Agreement with Allen & Company LLC to conduct an at-the-market offering of up to $100,000,000 of its Class A common stock. Under this arrangement, Ginkgo may, at its option, sell shares from time to time through or directly to Allen as sales agent under an effective Form S-3 shelf registration and a prospectus supplement dated September 4, 2025.
The agent will use commercially reasonable efforts to execute sales and will earn a commission of up to 3.0% of the gross proceeds from each share sale. Either party can terminate the agreement with written notice. Ginkgo currently expects any net proceeds, if shares are sold, to be used for general corporate purposes, including funding operations, technology development, working capital, and capital expenditures. The company notes there is no assurance any shares will actually be issued under this at-the-market program and highlights potential dilution and other risks in its risk factor disclosures.
Ginkgo Bioworks Holdings, Inc. is offering shares of its Class A common stock with an aggregate offering price of up to $100 million. The document reports an as-adjusted net tangible book value at June 30, 2025 of $642,728,535, or $10.00 per share, which the prospectus says represents an immediate increase of $0.13 per share to existing shareholders and an immediate dilution of $1.33 per share to new investors. The prospectus supplement references the company’s filings, including the Form 10-K for the fiscal year ended December 31, 2024 filed February 25, 2025, and states that the prospectus and supplement do not contain all information in the registration statement and exhibits. The company’s corporate website is listed as www.ginkgobioworks.com.
Ginkgo Bioworks Holdings, Inc. has reached a proposed settlement to resolve several stockholder derivative lawsuits filed on the company’s behalf in federal and Delaware courts. The company entered into a Stipulation and Agreement of Settlement on May 27, 2025, and on August 21, 2025, a federal court granted preliminary approval, ordered notice to stockholders, and set a final hearing for December 18, 2025 at 1:30 p.m. PST.
If the settlement receives final court approval, Ginkgo will receive a $4,125,000 payment funded by insurance, from which plaintiffs’ counsel plans to request $2,750,000 in fees and expenses. The company will also adopt and maintain specified corporate governance and other reforms, and the plaintiffs will dismiss the derivative actions with prejudice and provide releases related to the matters alleged.
Insider transactions by Ginkgo Bioworks Holdings, Inc. (DNA): Chief Financial Officer Steven P. Coen reported vesting-related activity on August 21-22, 2025. Two sets of restricted stock units (RSUs) converted into Class A common shares: 587 RSUs and 156 RSUs were deemed acquired on August 21, 2025. A subsequent open-market sale on August 22, 2025 sold 310 shares at $12.396 each to satisfy tax withholding related to vesting. Following these transactions, the reporting person beneficially owned 11,112 and 4,847 Class A shares in the respective RSU pools, with total reported Class A holdings shown across lines. The Form 4 was signed by an attorney-in-fact on August 26, 2025.
Ginkgo Bioworks (DNA) narrowed its quarterly loss but continues to burn cash. Q2-25 revenue fell 12% YoY to $49.6 M as Biosecurity sales halved to $10.5 M, offset partly by 8% growth in higher-margin Cell Engineering to $39.1 M. Aggressive cost cuts—R&D down 60% to $53.4 M and G&A down 35% to $43.3 M—drove operating loss to $65.5 M versus $222.9 M last year. Net loss improved to $60.3 M (-$1.10 per diluted share) from $217.2 M (-$4.23).
Liquidity shifted from cash to securities. Cash & equivalents dropped 64% to $203.6 M, with $262.6 M deployed into marketable debt securities (now $270.1 M). Operating cash burn was $91.8 M versus $173.6 M a year ago. Total assets declined 11% to $1.23 B; equity fell to $613 M.
Restructuring and future obligations remain key risks. The 2024 restructuring—workforce cut >50% and facility consolidation—added $3.7 M this quarter and is expected to reach up to $29 M. A probable $24 M Google Cloud commitment shortfall looms in Aug-25, and non-refundable DNA supply payments to Twist total $11 M over 2026-27. Deferred revenue slipped 17% since year-end to $102.9 M, hinting at softer pipeline. Shares outstanding after the 1-for-40 reverse split stood at 55.4 M.
Ginkgo Bioworks Holdings, Inc. (DNA) filed a Form 144 disclosing a planned disposition of 2,200 Class A shares (estimated value $31,020) through Fidelity Brokerage beginning on 08/06/2025. The shares, acquired via restricted-stock vesting on 10/17/2022, equal roughly 0.005% of the reported 46.34 million shares outstanding—an immaterial portion of DNA’s float.
The account holder, Austin Che, has already sold small 99-share lots over the last three months, totaling 3,366 shares for about $27 k plus a 2,200-share block on 07/09/2025 for $24.6 k. Form 144 requires the filer to certify no possession of undisclosed material information and, if relying on Rule 10b5-1, that a compliant trading plan exists. No operational, earnings, or strategic data accompany the notice; it solely signals modest insider liquidity. Given the limited size, analysts should expect negligible impact on DNA’s share supply or valuation.